coronavirus

The new coronavirus strain, first discovered in the central city of Wuhan, has caused alarm because of its connection to Severe Acute Respiratory Syndrome (SARS), which killed nearly 650 people across mainland China and Hong Kong in 2002-2003. More

Jump to
759 Results Found
  • COVID-19 | Achieving herd immunity difficult, new strains could cause reinfection: AIIMS chief Feb 20, 2021 10:53 PM IST

    COVID-19 | Achieving herd immunity difficult, new strains could cause reinfection: AIIMS chief

    The mutated version of coronavirus could 'escape' through the immune system developed by the body. In such a scenario, maintaining COVID-19-approporiate behaviour is of utmost necessity to reduce the pace of transmission, said Dr Randeep Guleria.

  • India to test travellers from Brazil, South Africa, UK after detecting new virus strains Feb 18, 2021 09:47 AM IST

    India to test travellers from Brazil, South Africa, UK after detecting new virus strains

    India, which has reported the highest number of overall COVID-19 cases after the United States, detected the South African variant in four people last month and the Brazilian one in one person this month.

  • Retail ad volumes on televisions declined 35% in 2020: Report Feb 08, 2021 05:37 PM IST

    Retail ad volumes on televisions declined 35% in 2020: Report

    Three months ended December 31 saw a 1.6 times ad volume growth compared to the first three months of 2020, data from the TAM AdEx report showed.

  • HCL Technologies offers employees bonus worth Rs 700 crore to mark $10-billion milestone Feb 08, 2021 09:47 AM IST

    HCL Technologies offers employees bonus worth Rs 700 crore to mark $10-billion milestone

    As per a statement from the company, all employees with one year of service or greater will receive a bonus, the equivalent of 10 days’ salary

  • Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1 Jan 22, 2021 12:43 PM IST

    Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1

    The overall incidence of 'adverse events' was 14–21 percent in all vaccine-treated groups, says the data published in Lancet. The company says the incidence of adverse events are noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.

  • 5 die in Serum Institute of India fire in Pune; no impact on Covishield Jan 21, 2021 03:25 PM IST

    5 die in Serum Institute of India fire in Pune; no impact on Covishield

    CEO Adar Poonawalla said equipment worth hundreds of crores were damaged in the fire, and the company is expected to face revenue loss of more than Rs 1,000 crore over the next one to two years.

  • Post-COVID-19 Job market | Hiring rises across board, digital roles see high demand: Report Jan 15, 2021 10:31 AM IST

    Post-COVID-19 Job market | Hiring rises across board, digital roles see high demand: Report

    “There is a clear correlation between the news of the vaccine rollout and hiring picking up," Sanjay Shetty, Head - strategic account management at Randstad India, said.

  • CII-Moneycontrol CEO Budget Survey | India Inc wants focus on public spending, manufacturing sector Jan 05, 2021 02:03 PM IST

    CII-Moneycontrol CEO Budget Survey | India Inc wants focus on public spending, manufacturing sector

    The poll was conducted by the Confederation of Indian Industry (CII), India’s oldest and largest industry body, exclusively for Moneycontrol. It took responses from more than 80 CEOs of the country’s top business houses. In it, the corporate honchos laid down their expectations from the government in and beyond the Union Budget 2021-22, as well as their thoughts on the economy in 2021.

  • Covaxin approval: Beyond the emotional outburst, here’s what Bharat Biotech’s Krishna Ella said about the vaccine Jan 05, 2021 01:23 PM IST

    Covaxin approval: Beyond the emotional outburst, here’s what Bharat Biotech’s Krishna Ella said about the vaccine

    The approval of Covaxin, which is still undergoing phase-3 clinical trials and yet to have efficacy data, has been roundly criticised. But Krishna Ella, Chairman and Managing Director of Bharat Biotech, the maker of Covaxin, feels a lot of that criticism is not justified. Here’s a look at what he had to say about its efficacy and immunogenicity data, administering it in ‘clinical trial mode’ and whether it is just a ‘back-up’ vaccine

  • Covaxin vs Covishield: Bharat Biotech, Serum Institute CEOs take a jab at each other, here is what they said Jan 05, 2021 12:36 PM IST

    Covaxin vs Covishield: Bharat Biotech, Serum Institute CEOs take a jab at each other, here is what they said

    Bharat Biotech Chairman Krishna Ella apparently hit back at Serum Institute of India chief Adar Poonawalla’s jibe calling vaccines other than those by AstraZeneca, Moderna and Pfizer as 'like water'.

  • 3-Point Analysis | Why is Bharat Biotech’s ‘Covaxin’ receiving backlash post approval? Jan 04, 2021 06:46 PM IST

    3-Point Analysis | Why is Bharat Biotech’s ‘Covaxin’ receiving backlash post approval?

    The Drug Controller General of India (DCGI) on January 3 granted permission for restricted emergency use of the AstraZeneca-Oxford University and Bharat Biotech Covid-19 vaccines. The approval was based on the recommendations of the Subject Expert Committee (SEC), which reviewed the data on safety and immunogenicity of the two vaccines. However, post the announcement it is India’s indigenous vaccine which has found itself in the middle of a controversy. Here’s why.

  • ITR filing | Government extends income tax return filing deadline to January 10 Dec 30, 2020 06:48 PM IST

    ITR filing | Government extends income tax return filing deadline to January 10

    In view of the COVID-19 pandemic, the Central Board of Indirect Taxes and Customs has also extended the due date for filing annual return under the Central Goods and Services Tax Act, 2017, to February 28.

  • UK nod to Oxford-AstraZeneca COVID-19 vaccine strengthens case for India approval Dec 30, 2020 03:19 PM IST

    UK nod to Oxford-AstraZeneca COVID-19 vaccine strengthens case for India approval

    The subject expert committee of the India's Central Drugs Standard Control Organisation is likely to meet later on December 30 to examine SII's emergency-use authorisation application for Oxford-AstraZeneca’s vaccine.

  • COVID-19 vaccine rollout: Dry run in four states next week Dec 25, 2020 02:39 PM IST

    COVID-19 vaccine rollout: Dry run in four states next week

    A dry run has been planned in four states to prepare for COVID-19 vaccine administration and assess readiness.

  • Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial Dec 24, 2020 10:15 PM IST

    Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial

    Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials.

  • Business Insight | How much money would India need to vaccinate its 1.3 billion population? Dec 17, 2020 08:46 PM IST

    Business Insight | How much money would India need to vaccinate its 1.3 billion population?

    As India prepares for a mass rollout of the COVID-19 vaccines, reports suggest that the country may need close to $1.8 billion to fund the first phase of the vaccination drive. This edition of Business Insight has everything you need to know about the drive.

  • Pfizer CEO Albert Bourla says in talks with US on more COVID-19 shots Dec 15, 2020 07:53 AM IST

    Pfizer CEO Albert Bourla says in talks with US on more COVID-19 shots

    Bourla told CNN in an interview that Pfizer is still negotiating with the U.S. on whether it will be able to deliver the vaccine in the second or third quarter of the year.

  • Big Story | Government releases SOP for COVID-19 vaccination drive; 100 people to be vaccinated per 'session' Dec 14, 2020 05:10 PM IST

    Big Story | Government releases SOP for COVID-19 vaccination drive; 100 people to be vaccinated per 'session'

    The Health Ministry has issued operational guidelines for the COVID-19 vaccination drive. The standard operating procedure (SOP) has been shared with all states and Union territories. Watch the video to know more

  • Explained l COVID vaccine: What is emergency use authorisation, how is it different from full approval and other details Dec 10, 2020 04:22 PM IST

    Explained l COVID vaccine: What is emergency use authorisation, how is it different from full approval and other details

    Bharat Biotech’s COVID-19 vaccines were "not considered" for emergency use authorisation on December 9 over lack of data. But what is emergency use authorisation and how is it different from full approval? What is the process of getting a EUA in India and is it safe to use? What are the risks involved? Here are four key questions answered about the new COVID-19 buzz word - EUA

  • COVID-19 vaccine: Expert panel to review Pfizer, Serum, Bharat Biotech's emergency use applications today Dec 09, 2020 10:02 AM IST

    COVID-19 vaccine: Expert panel to review Pfizer, Serum, Bharat Biotech's emergency use applications today

    After evaluation, the panel will recommend to the DCGI whether emergency use approval for the vaccine candidates should be granted or not.

  • Exclusive | Oyo lays off another 600-800 employees as it moves to a revenue-sharing model Dec 08, 2020 10:24 AM IST

    Exclusive | Oyo lays off another 600-800 employees as it moves to a revenue-sharing model

    Until early this year, the company had around 10,000 employees in the country. Now, the number is estimated to have come down to less than 2,500, with Oyo shifting to a lean model and exiting operations and renovations.

  • Big Story | Serum Institute seeks emergency clearance in India for COVID-19 vaccine. What happens next? Dec 07, 2020 06:50 PM IST

    Big Story | Serum Institute seeks emergency clearance in India for COVID-19 vaccine. What happens next?

    Serum Institute is now seeking the DCGI nod For emergency use authorisation of its vaccine candidate Covishield In India. More here.

  • New smartphone-based COVID-19 test gives results in less than 30 minutes Dec 07, 2020 02:31 PM IST

    New smartphone-based COVID-19 test gives results in less than 30 minutes

    According to the research published in the journal Cell, the new diagnostic test can not only generate a positive or negative result, it also measures the viral load -- the concentration of virus -- in a given sample.

  • Pfizer has sought emergency approval for COVID-19 vaccine in India: Government adviser Dec 07, 2020 07:57 AM IST

    Pfizer has sought emergency approval for COVID-19 vaccine in India: Government adviser

    The U.S. company, whose vaccine was recently approved in Britain, approached Indian authorities on Saturday, V.K. Paul, who is advising the government on COVID-19 matters, said.

  • Oxford-AstraZeneca vaccine: Serum Institute seeks DCGI nod for emergency use authorisation of Covishield in India Dec 07, 2020 07:56 AM IST

    Oxford-AstraZeneca vaccine: Serum Institute seeks DCGI nod for emergency use authorisation of Covishield in India

    SII is the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking authorisation for a coronavirus vaccine in India.

Sections